News & Media

September 17, 2024 ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
Read Article

July 24, 2024 ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
Read Article

December 11, 2023 ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
Read Article

October 24, 2023 ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
Read Article

October 17, 2023 ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
Read Article

September 19, 2023 ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
Read Article

May 24, 2023 ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
Read Article

April 25, 2023 ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
Read Article

January 17, 2023 ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
Read Article

November 15, 2022 ImmunOs Therapeutics’ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
Read Article

October 17, 2022 ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
Read Article

October 4, 2022 ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors.
Read Article

June 7, 2022 ImmunOs Therapeutics Raises $74 Million Series B Financing Round.
Read Article

December 6, 2021 ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer.
Read Article

November 15, 2021 ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro.
Read Article

October 13, 2021 ImmunOs Therapeutics AG Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC).
Read Article

September 30, 2021 ImmunOs Therapeutics AG today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.
Read Article

September 1, 2021 ImmunOs Therapeutics AG Appoints Seasoned Exec Jeffrey Abbey as Chief Operating Officer and High-Caliber Clinical and Scientific Advisors.
Read Article

April 12, 2021 ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases.
Read Article

​​November 13, 2020 ImmunOs Therapeutics AG Presents Data from their iosH2 Program at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting.
Read Article​

December 10, 2019 ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials.
Read Article

September 18, 2018 UZH Life Sciences Fund and Schroder Adveq Invest in ImmunOs Therapeutics AG to Support Advancement of their Immunotherapy Platform for Cancer.
Read Article​